Tubulis

Cancer mutation precision medicine oncology targeted
Biotech

ESMO: Tubulis' next-gen ADC lives up to hype with 59% ORR

Tubulis’ next-generation ADC has been tied to an overall response rate of 59% as the German biotech tastes its first clinical success.
James Waldron Oct 19, 2025 4:15am
Graphic images of different entities adding money to a pile

Tubulis touts $361M series C as next-gen ADC data drop nears

Oct 15, 2025 5:01am
Alps parachute rainbow mountains

Takeda taps longtime Lilly exec as US head—Chutes & Ladders

Sep 12, 2025 8:30am
Parachute over La Jolla California

J&J vet jumps to Affinia—Chutes & Ladders

Feb 7, 2025 8:30am
Businessman climbing steps to pluck a star from the sky

Gilead advances ADC dreams with potential $465M deal

Dec 3, 2024 10:54am
Fierce 15 Hero

Introducing Fierce Biotech's 2024 Fierce 15

Aug 5, 2024 6:00am